Abstract:Objective To explore the demethylation effect of P15INK4 Bgene in myelodysplastic syndrome( MDS)-derived cell line SKM-1 induced by DNA methyltransferase inhibitor Decitabine( DAC). Methods SKM-1 cells in exponential growth phase were set up for 4 groups. 3 DAC groups of SKM-1 cells were treated with 1. 5,3. 0 and 6. 0 mol / L DAC for48 h,untreated SKM-1 cells were the control group. The methylation of P15INK4 Bgene,the expression of P15INK4 Bgene mRNA,the cellular proliferation,the cell cycle and the cellular early apoptosis were detected by methylation specific PCR( MSP),real time fluorescent RT-PCR,CFSE methods,propidium iodide( PI) staining and annexin V-FITC/PI double la-beling. Results( 1) The control group was entirely methylated with P15INK4 Bgene,while 1. 5 mol / L,3. 0 mol / L and 6. 0 mol / L DAC groups underwent partial methylation and showed a unmethylated and darkening strip. The degree of P15INK4 B gene meth-ylation was lower in the groups with higher concentrations of DAC.( 2) The expression of P15INK4 Bgene mRNA in the control group,1. 5 mol / L,3. 0 mol / L and 6. 0 mol / L DAC groups were 1. 00 ± 0. 12,0. 91 ± 0. 13,0. 51 ± 0. 06 and 0. 43 ± 0. 04,respectively. Compared with control group,the expression of P15 I INK4B gene mRNA in DAC groups significantly decreased( P 0. 05). There were no statistical significant differences when compared with DAC groups( P 0. 05).( 3) The MFI of CFSE in the control group,1. 5 mol / L,3. 0 mol / L and 6. 0 mol / L DAC groups were 51. 67 ± 1. 61,55. 33 ± 2. 28,56. 33 ±2. 50 and 55. 71 ± 2. 87,respectively. Compared with control group,the 3. 0 mol / L DAC group significantly decreased( P 0. 05). There were no statistical significances when compared with DAC groups( P 0. 05). 4). The proportion of G1 phase cells in the control group,1. 5 mol / L,3. 0 mol / L and 6. 0 mol / L DAC groups were( 55. 78 ± 3. 61) %,( 48. 12 ±2. 93) %,( 51. 69 ± 1. 60) % and( 46. 71 ± 1. 54) %,respectively. The proportion of S phase cells in the control group,1. 5 mol / L,3. 0 mol / L and 6. 0 mol / L DAC groups were( 44. 22 ± 3. 61) %,( 51. 88 ± 2. 93) %,( 48. 31 ± 1. 60) % and( 53. 29 ± 1. 54) %,respectively. Compared with control group,the proportion of G1 phase cells in 1. 5 mol/L group and6. 0 mol / L DAC group decreased significantly( P 0. 05). With the paired comparison in DAC groups,there was statistical significance between 6. 0 mol / L group and 3. 0 mol / L groups( P 0. 05). 5). The early apoptosis rates in the control group,1. 5 mol / L,3. 0 mol / L and 6. 0 mol / L DAC group were( 2. 91 ± 0. 26) %,( 7. 77 ± 0. 22) %,( 12. 45 ± 0. 28) %and( 13. 86 ± 0. 27) %,respectively. Compared with control group,the early apoptosis rates in DAC groups increased significantly( P 0. 05). There were statistical significance when compared with DAC groups( P 0. 05). Conclusion DAC an induce demethylation of P15INK4 B gene,suppress cellular proliferation,arrest cells in S phase,and promote cellular early apoptosis. The apoptosis rates increases with the increases of DAC concentration in SKM-1 cells. However,P15INK4 Bgene mRNA re-expression with P15INK4 Bgene demethylation did not occur simultaneously.

Defetoxamine (DFO) induces the demethylation of P15INK4B gene in myelodysplastic syndrome (MDS) cell line SKM-1

[Methylation of P15INK4B Gene in Patients with Myelodysplastic Syndromes and Demethylating Effects of Drugs].

Deferoxamine Enhanced Mitochondrial Iron Accumulation and Promoted Cell Migration in Triple-Negative MDA-MB-231 Breast Cancer Cells Via a ROS-Dependent Mechanism

Synergistic inhibitory effects of deferasirox in combination with decitabine on leukemia cell lines SKM-1, THP-1, and K-562.

[Arsenic Trioxide Induced P15ink4b Gene Expression in Myelodysplastic Syndrome Cell Line MUTZ-1].

Study on Methylation of P15ink4b Gene and Its Mechanisms in Patients with Myelodysplastic Syndrome and Leukemia.

Effect of deferasirox + erythropoietin vs erythropoietin on erythroid response in Low/Int-1-risk MDS patients: Results of the phase II KALLISTO trial.

The impact of DNA methyltransferase inhibitor decitabine on P15INK4B gene methylation status in SKM-1 cells

The iron chelator deferasirox affects redox signalling in haematopoietic stem/progenitor cells

Iron chelation inhibits cancer cell growth and modulates global histone methylation status in colorectal cancer

Deferoxamine Suppresses Esophageal Squamous Cell Carcinoma Cell Growth Via ERK1/2 Mediated Mitochondrial Dysfunction

Deferasirox, an iron chelator, impacts myeloid differentiation by modulating NF-kB activity via mitochondrial ROS

Deferoxamine alleviates chondrocyte senescence and osteoarthritis progression by maintaining iron homeostasis

Targeting Mitochondrial Iron Metabolism Suppresses Tumor Growth and Metastasis by Inducing Mitochondrial Dysfunction and Mitophagy

Effects of Deferoxamine on the Osteogenic Differentiation of Human Periodontal Ligament Cells.

Deferoxamine accelerates endothelial progenitor cell senescence and compromises angiogenesis

Effects of Deferoxamine on the Repair Ability of Dental Pulp Cells In Vitro

Deferasirox Causes Leukaemia Cell Death through Nrf2-Induced Ferroptosis

Deferasirox induces cyclin D1 degradation and apoptosis in mantle cell lymphoma in a reactive oxygen species‐ and GSK3β‐dependent mechanism

Ferroptosis Inhibition with Deferoxamine Alleviates Radiation-Induced Fibrosis

HIF2α activation and mitochondrial deficit due to iron chelation cause retinal atrophy